Semaglutide vs Mazdutide

Single-receptor GLP-1 vs dual GLP-1/glucagon: how the established incretin compares to Innovent's Asia-first next-generation candidate.

Semaglutide is the clinical baseline for GLP-1 receptor agonism. Mazdutide (LY3305677) is a dual GLP-1 / glucagon agonist developed by Eli Lilly and licensed to Innovent Biologics — it has produced strong Phase-3 weight-loss data in Asia and is emerging as a serious next-generation candidate.

Side-by-side comparison

	Semaglutide	mazdutide
Class	GLP-1 receptor agonist	Dual GLP-1 / glucagon receptor agonist
Receptors activated	1 (GLP-1)	2 (GLP-1 + glucagon)
FDA status	Approved (multiple brands)	Investigational (approved in China 2025)
Dosing cadence	Once weekly	Once weekly
Headline weight reduction	~15% (STEP, 68 wk)	~15–18% (GLORY-1, 48 wk)
Differentiator	Broadest clinical evidence base	Adds glucagon-driven energy expenditure

About Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is one of the most-studied incretin-class molecules and underpins several FDA-approved branded medications in clinical settings.

Semaglutide mimics endogenous GLP-1, stimulating glucose-dependent insulin secretion, slowing gastric emptying, and acting on central appetite-regulation pathways.

• Metabolic and weight-management research
• Glycemic regulation studies
• Appetite-pathway research

The takeaway

Semaglutide has the deepest clinical dataset and global availability. Mazdutide's dual-receptor design and Phase-3 Asia data make it the most credible near-term challenger; head-to-head trials outside Asia are still pending.

How to read this comparison

The table above compares published characteristics, not outcomes for any individual. Mechanism, half-life, and dosing cadence are properties of the molecule; response, tolerability, and suitability are properties of the person. Trial averages describe populations and say nothing definitive about a single case.

• Check which compound has approved clinical use for the indication you care about, and which does not.
• Compare half-life and dosing cadence against how consistently a protocol can actually be followed.
• Read both individual reference pages before drawing a conclusion from the table alone.
• Any clinical decision belongs with a licensed practitioner who knows the full history.

Important

All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.

Frequently asked questions

How is semaglutide different from tirzepatide?

Semaglutide targets the GLP-1 receptor alone. Tirzepatide is a dual GIP/GLP-1 receptor agonist, hitting two incretin pathways at once.

Do I need a prescription for clinical use?

Yes. Any clinical use must be directed by a licensed medical practitioner. Research-use product is supplied for investigational purposes only.